Home » Blog » Obama Administration Pushes for Medicare Part D Drug Discounts and Provider Specialists Heading for the Exit?

Obama Administration Pushes for Medicare Part D Drug Discounts and Provider Specialists Heading for the Exit?


IP Blog | Dave Melin | February 8, 2015

BioBlog Weekly oncologyThis week in healthcare, the Obama administration said it would seek authority to negotiate prices for high-cost drugs under the government’s Medicare Part D program and a look ahead to the impact of the 2016 U.S. budget on healthcare with analysis on the federal government’s shift away from fee-for-service payments to specialist doctors.

What Obama’s 2016 budget will mean for healthcare providers

FierceHealthcare digs into the details of President Obama’s budget proposal for 2016 and what it means for healthcare, including a $215 million Precision Medicine Initiative and the expansion of national cancer subgroup research.

Obama administration seeks to negotiate Medicare drug prices

“The Obama administration said on Monday it would seek authority to negotiate prices for high-cost drugs under the government’s Medicare Part D program, which offers private drug coverage for senior citizens and the disabled.”

Specialist Doctors Head for Exit as U.S. Shifts Payments

At the end of January, Health and Human Services Secretary Sylvia Burwell announced her intentions that “at least 30 percent of Medicare’s $362 billion in fee-for-service payments moved, by 2017, into new programs that demand accountability from doctors and hospitals and in some cases penalize them if their care doesn’t meet quality and efficiency standards.” In the face of this move away from fee-for-service, this leaves many physicians — especially specialists — worried for the future.

Biosimilar Competition In The United States: Statutory Incentives, Payers, And Pharmacy Benefit Managers

In this HealthAffairs article, the authors set out to “compare the legislative framework governing small-molecule generics to that which regulates follow-on biologics, and [to] examine management tools that are likely to be most successful in promoting biosimilars’ adoption.”

Analysis: High-Cost Blood Cancer Drugs Deliver High Value

While some denounce high-cost blood cancer drugs for their large price tag, “a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.”

Outgoing FDA Chief Saw Changes to Food Safety, Tobacco Rules

Last week, FDA commissioner Margaret Hamburg announced her resignation. She will be replaced by the FDA’s chief scientist, Stephen Ostroff, who will serve as the acting head official.

Exclusive: Apple’s health tech takes early lead among top hospitals

Phone tech giants Apple, Google, and Samsung don’t just compete in the world of smartphones — now they’re fighting to top the health tech market as well. In this race, Apple currently has the lead: “Fourteen of 23 top hospitals contacted by Reuters said they have rolled out a pilot program of Apple’s HealthKit service,” which holds patient information.

Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *